This is a summary of the European public assessment report (EPAR) for Prialt. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Prialt.
Therapeutic Indication
### Therapeutic indication Ziconotide is indicated for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia.
Therapeutic Area (MeSH)
ATC Code
N02BG08
ATC Item
ziconotide
Pharmacotherapeutic Group
Analgesics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ziconotide | N/A | 齐考诺肽 |
EMA Name
Prialt
Medicine Name
Prialt
Aliases
N/ANo risk management plan link.
